Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation

[1]  Chia-Yang Li,et al.  Proteasome Inhibitors Decrease the Viability of Pulmonary Arterial Smooth Muscle Cells by Restoring Mitofusin-2 Expression under Hypoxic Conditions , 2022, Biomedicines.

[2]  Y. Gong,et al.  Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta‐analysis of randomized clinical trials , 2021, Hematological oncology.

[3]  K. Salaita,et al.  Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes , 2021, Journal of the American Heart Association.

[4]  R. A. Fan,et al.  Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism , 2021, International journal of molecular sciences.

[5]  D. Faller,et al.  A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis , 2021, Leukemia.

[6]  Preethi William,et al.  Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. , 2021, Cardiovascular & hematological disorders drug targets.

[7]  Jiankai Zhong,et al.  Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis , 2020, Drug and chemical toxicology.

[8]  M. Gertz,et al.  Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management , 2020, Current Oncology Reports.

[9]  Lei Zhang,et al.  Role of Parkin-mediated mitophagy in glucocorticoid-induced cardiomyocyte maturation. , 2020, Life sciences.

[10]  R. Parenti,et al.  Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells , 2020, Biomolecules.

[11]  K. Arga,et al.  Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib , 2020, Redox biology.

[12]  P. Donoso,et al.  Inhibition of the proteasome preserves Mitofusin-2 and mitochondrial integrity, protecting cardiomyocytes during ischemia-reperfusion injury. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[13]  H. Overkleeft,et al.  Carfilzomib Induces Cardiotoxicity Via ß5/ß2-Specific Proteasome Subunit Inhibition Pattern , 2019, Blood.

[14]  B. Xin,et al.  Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors. , 2019, Cell chemical biology.

[15]  J. Bergquist,et al.  Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib , 2018, Scientific Reports.

[16]  B. Hasinoff,et al.  Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs , 2018, Cardiovascular Toxicology.

[17]  H. Goldschmidt,et al.  Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials , 2018, Hematological oncology.

[18]  J. Moreb,et al.  Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis , 2018, Leukemia & lymphoma.

[19]  J. Laubach,et al.  Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma , 2018, British journal of haematology.

[20]  Joel N Meyer,et al.  Mitochondrial fusion, fission, and mitochondrial toxicity. , 2017, Toxicology.

[21]  W. Frishman,et al.  Cardiovascular Complications of Proteasome Inhibitors Used in Multiple Myeloma , 2017, Cardiology in review.

[22]  Xinyang Hu,et al.  Molecular regulation of mitochondrial dynamics in cardiac disease. , 2017, Biochimica et biophysica acta. Molecular cell research.

[23]  Jennifer E. Gilda,et al.  Proteasome dysfunction in cardiomyopathies , 2017, The Journal of physiology.

[24]  S. Vincent Rajkumar,et al.  Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors , 2017, American journal of hematology.

[25]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[26]  Mario van der Stelt,et al.  A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. , 2016, Angewandte Chemie.

[27]  M. Shirley.  Ixazomib: First Global Approval , 2016, Drugs.

[28]  P. Ferdinandy,et al.  Drug-induced mitochondrial dysfunction and cardiotoxicity. , 2015, American journal of physiology. Heart and circulatory physiology.

[29]  B. Ky,et al.  Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. , 2015, Journal of cardiac failure.

[30]  S. Hoppins.  The regulation of mitochondrial dynamics. , 2014, Current opinion in cell biology.

[31]  G. Kroemer,et al.  Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance , 2014, Cell cycle.

[32]  R. Tian,et al.  Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. , 2013, Circulation research.

[33]  T. Prolla,et al.  Mitochondrial Fusion Is Required for mtDNA Stability in Skeletal Muscle and Tolerance of mtDNA Mutations , 2010, Cell.

[34]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[35]  F. Buttgereit,et al.  Genomic and nongenomic effects of glucocorticoids , 2008, Nature Clinical Practice Rheumatology.

[36]  S. Demo,et al.  Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. , 2007, Cancer research.

[37]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[38]  R. Puvanakrishnan,et al.  Dexamethasone induced alterations in enzymatic and nonenzymatic antioxidant status in heart and kidney of rats , 1998, Molecular and Cellular Biochemistry.

[39]  P. Ritz,et al.  Mitochondrial effects of dexamethasone imply both membrane and cytosolic-initiated pathways in HepG2 cells. , 2008, The international journal of biochemistry & cell biology.

[40]  M. Majetschak,et al.  Distribution and interrelationship of ubiquitin proteasome pathway component activities and ubiquitin pools in various porcine tissues. , 2007, Physiological research.

[41]  Thomas D. Schmittgen,et al.  Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method , 2022 .